A Safety and Efficacy Study of SHR3680 in Metastatic Castration-Resistant Prostate Cancer Patients

NCT02691975 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

197

Enrollment

INDUSTRY

Sponsor class

Conditions

Hormone Refractory Prostate Cancer
Metastatic Prostate Carcinoma

Interventions

DRUG: SHR3680

Sponsor

Jiangsu HengRui Medicine Co., Ltd.